Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
1.88
Dollar change
+0.04
Percentage change
2.17
%
IndexRUT P/E- EPS (ttm)-0.24 Insider Own1.68% Shs Outstand256.57M Perf Week9.94%
Market Cap483.82M Forward P/E- EPS next Y-0.29 Insider Trans0.00% Shs Float253.04M Perf Month23.28%
Income-59.98M PEG- EPS next Q-0.05 Inst Own12.79% Short Float20.99% Perf Quarter11.24%
Sales2.42M P/S199.92 EPS this Y16.67% Inst Trans-2.90% Short Ratio7.93 Perf Half Y221.20%
Book/sh0.12 P/B15.99 EPS next Y-35.38% ROA-81.00% Short Interest53.12M Perf Year213.91%
Cash/sh0.10 P/C18.34 EPS next 5Y- ROE-113.11% 52W Range0.34 - 2.11 Perf YTD226.96%
Dividend Est.- P/FCF- EPS past 5Y41.20% ROI-170.36% 52W High-10.69% Beta3.66
Dividend TTM- Quick Ratio1.87 Sales past 5Y8.52% Gross Margin65.21% 52W Low444.93% ATR (14)0.13
Dividend Ex-Date- Current Ratio1.87 EPS Y/Y TTM33.96% Oper. Margin-2595.87% RSI (14)66.67 Volatility6.07% 9.16%
Employees65 Debt/Eq0.23 Sales Y/Y TTM- Profit Margin-2475.48% Recom1.00 Target Price6.67
Option/ShortYes / Yes LT Debt/Eq0.16 EPS Q/Q36.61% Payout- Rel Volume0.80 Prev Close1.84
Sales Surprise- EPS Surprise21.01% Sales Q/Q- EarningsMay 14 BMO Avg Volume6.70M Price1.88
SMA2024.09% SMA5016.65% SMA20097.57% Trades Volume5,377,652 Change2.17%
Date Action Analyst Rating Change Price Target Change
Mar-01-23Upgrade Chardan Capital Markets Neutral → Buy $3.50
Aug-23-22Initiated Mizuho Buy $5
Jun-15-22Resumed ROTH Capital Buy $8
Jun-02-22Initiated Cantor Fitzgerald Overweight $4.50
Jul-26-21Initiated Noble Capital Markets Outperform
Jun-11-21Downgrade ROTH Capital Buy → Neutral $10 → $6
May-07-21Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-09-21Downgrade Chardan Capital Markets Buy → Neutral $0.70 → $13
Feb-04-21Upgrade H.C. Wainwright Neutral → Buy $4.50
Jul-11-24 08:45AM
Jul-06-24 06:39AM
Jun-24-24 09:40AM
06:40AM
Jun-21-24 07:00AM
08:23AM Loading…
Jun-20-24 08:23AM
06:30AM
Jun-14-24 07:15AM
Jun-05-24 09:25AM
May-31-24 08:36AM
May-29-24 07:15AM
May-28-24 07:02AM
May-24-24 08:10AM
May-20-24 07:00AM
May-15-24 07:30AM
06:30AM Loading…
06:30AM
03:02AM
01:12AM
May-14-24 11:53AM
08:00AM
06:43AM
May-10-24 04:05PM
07:45AM
May-08-24 06:00AM
May-03-24 07:30AM
May-02-24 07:15AM
Apr-29-24 08:30AM
06:45AM
Apr-28-24 11:59AM
Apr-26-24 12:35PM
09:05AM Loading…
09:05AM
06:30AM
Apr-19-24 07:13AM
Apr-16-24 10:53PM
Apr-12-24 07:30AM
Apr-10-24 07:02AM
Apr-08-24 12:13PM
10:57AM
06:30AM
Apr-05-24 03:30PM
07:02AM
Apr-02-24 10:50PM
07:00PM
03:15PM
08:00AM
Apr-01-24 06:08PM
05:43PM
Mar-25-24 11:58AM
07:32AM
Mar-18-24 06:30AM
Mar-13-24 08:00AM
Mar-07-24 05:28AM
Mar-06-24 07:30AM
Feb-28-24 08:00AM
Feb-26-24 04:34PM
08:30AM
Feb-22-24 04:05PM
12:56PM
Feb-21-24 04:05PM
Feb-20-24 10:26AM
Feb-14-24 07:30AM
Jan-31-24 08:00AM
Jan-16-24 07:30AM
Dec-21-23 06:30AM
Dec-19-23 07:30AM
Dec-13-23 07:30AM
Nov-29-23 07:30AM
Nov-10-23 01:54PM
07:30AM
02:07AM
Nov-09-23 11:45AM
08:38AM
07:00AM
06:30AM
Nov-07-23 07:45AM
Nov-02-23 07:30AM
Oct-10-23 09:58AM
06:30AM
Oct-04-23 07:00AM
Sep-29-23 07:30AM
Sep-27-23 07:30PM
Sep-21-23 07:30AM
Sep-20-23 08:00AM
Sep-13-23 08:15AM
Sep-12-23 07:30PM
Aug-24-23 09:48AM
Aug-23-23 02:05AM
Aug-22-23 12:00PM
Aug-21-23 04:32PM
Aug-18-23 04:39PM
Jul-25-23 08:58PM
Jul-13-23 07:00AM
Jun-30-23 08:00AM
Jun-09-23 04:05PM
Jun-05-23 07:02AM
May-25-23 02:00PM
May-24-23 08:36AM
May-23-23 04:01PM
08:00AM
May-05-23 03:00PM
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.